Key takeaways for New Jersey
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • NJ FamilyCare coverage rules apply for Insulin Resistance patients in New Jersey — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
New Jersey-specific context
New Jersey has telehealth access concentrated in Newark, Jersey City, Paterson metros, with additional reach to Elizabeth and Edison. RWJBarnabas Health, Hackensack Meridian Health, Atlantic Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nj.gov/health.
New Jerseytelehealth & pricing rules
- • New Jersey requires a live video consultation before a GLP-1 prescription.
- • New Jersey allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Jersey: ~$328/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.